title: Topical cyclosporine A in the prevention of pterygium recurrence.
abstract: OBJECTIVE
  To investigate the efficacy and safety of postoperative topical cyclosporine A 0.05% (tCsA) (Restasis, Allergan Pharmaceutical) eye drops in preventing the recurrence of pterygium.
  
  
  METHODS
  31 patients with bilateral pterygium were examined between January 2006 and February 2007. During a 1-year follow-up, the right eyes of the patients assigned as the treatment group were treated by tCsA and the left eyes were considered as the control group.
  
  
  RESULTS
  The pterygium recurred in 4 (12.9%) of 31 right eyes in the treatment group and in 14 (45.2%) of 31 left eyes in the control group (p = 0.005). The mean follow-up +/- SD was 9.39 +/- 4.14 months (range, 1 to 12 months). The control group had a 7.37 times higher risk of recurrence in pterygium compared with the treatment group (OR = 0.1357, p = 0.0051). A statistically significant difference in recurrence-free probabilities was found for the treatment and control groups (log-rank test; p = 0.006). A multivariate Cox regression model showed that age (p = 0.0093) and tCsA (p = 0.0103) were independent statistically significant impacts on recurrence-free time for pterygium.
  
  
  CONCLUSIONS
  This study suggests that primary excision of pterygium with postoperative instillation of 0.05% cyclosporine is both safe and efficient.
authors.affiliation: Department of Ophthalmology, Ankara Education and Research Hospital, Ankara, Turkey. esattok@yahoo.com
authors.forename: Ozlem
authors.initials: O
authors.lastname: Yalcin Tok
authors.forename: Ayse
authors.initials: A
authors.lastname: Burcu Nurozler
authors.forename: Gul
authors.initials: G
authors.lastname: Ergun
authors.forename: Fatma
authors.initials: F
authors.lastname: Akbas Kocaoglu
authors.forename: Sunay
authors.initials: S
authors.lastname: Duman